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Correspondence
A trial of metoclopramide vs sumatriptan for the
emergency department treatment of migraines
To the Editor: Friedman et al.1 compared metoclopramide vs
sumatriptan for the emergency department (ED) treatment of mi-
graine with interest. Utilizing diphenhydramine in combination
with metoclopramide may have affected the results of the compar-
ison since diphenhydramine has been used independently as a
treatment for migraine. The suggested treatment is one to three
doses daily (25 to 50 mg) either intramuscularly or intravenously
and is used essentially as an abortive agent.2 Diphenhydramine
has also been recommended for severe attacks of migraine during
pregnancy, with metoclopramide being restricted to the third
trimester.3
There has been a recent study comparing IV diphenhydramine
vs IV dihydroergotamine (DHE)-45 in the treatment of severe
migraine headache.4 Combination treatment may provide benefit
for patients who don’t respond to individual agents, such as com-
bining metoclopramide with a triptan in triptan-nonresponsive
migraineurs.5
Used alone, diphenhydramine may have therapeutic effective-
ness for headaches in addition to preventing akathisias and other
dystonic reactions for which it was utilized in the present study. It
has been used independently as a treatment for migraine and
could have some potential for enhancing the effect of triptans in
triptan nonresponders if used in combination therapy.
However, the combination of metoclopramide and diphenhy-
dramine appears to be a reasonable treatment based on the favor-
able outcome on headache noted in the comparison with
sumatriptan.
Steven R. Brenner, MD, Saint Louis, MO
Reply from the Authors: We thank Dr. Brenner for his relevant
and informative summary of the role of diphenhydramine in
migraines.
We agree that we tested the efficacy of metoclopramide com-
bined with diphenhydramine in our study.1 We recommend using
the combination of metoclopramide and diphenhydramine for ED
patients with acute migraines. Although some data exist support-
ing a role for diphenhydramine alone as migraine treatment,4 this
is not yet established.
We agree that there might be a role for combination therapy in
ED patients with severe migraines. As yet, there is no treatment
paradigm for ED care comparable to the stratified care plan devel-
oped for outpatient migraine management.6 Thus, we do not know
which ED patients with acute migraines require multidrug ther-
apy initially and which patients will be satisfactorily treated with
a single agent.
To the Editor: In their recent article, Friedman et al.1 conclude
that metoclopramide 20 mg IV may be preferable to sumatriptan 6
mg subcutaneous for the acute treatment of migraine attacks in
the ED.
In the protocol of this study it appears that, in the metoclopra-
mide arm, patients received 20 mg IV infusions every 30 minutes
(average 2.2 infusions) of which the first and third contained 25
mg diphenhydramine, while the infusions in the sumatriptan arm
only contained saline. If this is correct, it introduces considerable
bias because diphenhydramine may have antimigraine properties.
Diphenhydramine is commonly used IV to treat migraine attacks
alone4 or combined with analgesics.7 Histamine may trigger a
migraine attack by increasing NO via H1 receptors.8
At best, the authors can conclude that the association of re-
peated high dose IV metoclopramide and diphenhydramine has
(at 2 hours) comparable efficacy to a single subcutaneous
sumatriptan injection in severe migraine attacks. Another recent
study9 suggested that metoclopramide alone may not be sufficient
to interrupt a migraine attack showing that it was not better than
placebo. However, in contrast to Friedman et al.’s study,1 metoclo-
pramide was given as a single 10 mg injection and the primary
outcome measure was pain relief at 30 minutes.
Marta Allena, Delphine Magis, Jean Schoenen, Liege, Belgium
Reply from the Authors:We thank Allena et al. for their review
of the role of metoclopramide and diphenhydramine in the treat-
ment of acute migraines. We agree that we tested the efficacy of
metoclopramide combined with diphenhydramine in our study.1
We recommend using the combination of metoclopramide and di-
phenhydramine for ED patients with acute migraines.
Allena et al. hypothesize that the reason our antimigraine
regimen was effective was the unrecognized benefit of diphenhy-
dramine. Although some data suggest efficacy of diphenhydra-
mine alone as migraine treatment,4 we believe this is still unclear.
However, metoclopramide has been demonstrated to be more
effective than placebo and other comparators in multiple studies
(table). A recent metaanalysis similarly concluded that metoclo-
pramide was an effective antimigraine treatment.10
We disagree with Allena et al.’s interpretation of the study by
Cete et al.9 In this study, 65% of subjects randomized to placebo
required rescue medication at 30 minutes, while only 38% of sub-
jects randomized to metoclopramide required rescue medication.
At 30 minutes, placebo patients had improved on the VAS by 25
while metoclopramide patients had improved by 40. This differ-
ence of 15 in the VAS point estimates suggests a clinically rele-
vant difference,11 even if the study was not sufficiently powered to
achieve statistical significance for this finding.
Perhaps the dose of metoclopramide is relevant. Of the trials
listed in the table, the two that used more aggressive dosing of
metoclopramide (similar to our design) had excellent results.
Dose-finding studies are needed to evaluate this hypothesis.
B.W. Friedman, MD, MS, J. Corbo, MD, R.B. Lipton, MD,
P.E. Bijur, PhD, D. Esses, MD, E.J. Gallagher, MD, Bronx, NY
Table Dosing of previous metoclopramide studies
Author, year Metoclopramide dose Comparator Metoclopramide results
Tek, 1990 MCP 10 mg IV Placebo 67% with sufficient relief at 1 h
Ellis, 1993 MCP 10 mg IV Ibuprofen, placebo Change in median VAS:
30 min–3.5
60 min–7.5
Cameron, 1995 MCP 0.1 mg/kg  3 IV Chlorpromazine 66% with 70% relief at 1 h
Coppola, 1995 MCP 10 mg IV Prochlorperazine, placebo 48% with relief at 30 min
Jones, 1996 MCP 10 mg IM Prochlorperazine, placebo 48% with relief at 1 h
Esteban-Morales, 1999 MCP 10 mg IV Sumatriptan 6 mg Relief: 60% at 30 min, 100% at 60 min
Pain free: 25% at 30 min, 65% at 60 min
Corbo, 2001 MCP 20 mg  3 IV MCP  magnesium 96% with 50% reduction in pain by 45 min
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Chronic inflammatory demyelinating
polyradiculoneuropathy: MRI study of brain and
spinal cord
To the Editor: We read with great interest the recent article by
Laura et al.1 concerning cervical spinal cord atrophy in chronic
inflammatory demyelinating polyradiculoneuropathy (CIDP).
They reported that the mean cervical cord area was significantly
smaller in patients with CIDP compared to controls. We would
like to report our experience regarding spinal cord findings in
CIDP.
We had five cases with definite CIDP2 and evaluated other
demyelinating lesions than peripheral nerves. In our experience,
no lesions were found in the intracranial, cervical, thoracic, and
lumbar spinal cords. No spinal cord atrophy was seen.
We would be interested to find out the authors’ responses to
some issues:
First, they reported that cord atrophy was confirmed in the
cervical lesion. Were the thoracic cords normal?
Second, they demonstrated cervical and thoracic cords which
seem to show cervical spondylotic lesions and seven cases were
more than 50 years old in their series. In our cases, all of the cases
were more than 50 years old, and all of our cases had spondylotic
lesions in the cervical or lumbar cord. It is possible that spondy-
lotic lesions may contribute to cord atrophy.
Third, no associations were found between cord area and dis-
ease duration. What factor(s) determined cord atrophy in CIDP? In
addition to degeneration secondary to axonal loss,3 spondylotic le-
sions may contribute to cord atrophy in CIDP. Their finding of cord
atrophy in CIDP is interesting and warrants further investigation.
Y. Iwasaki, MD, O. Igarashi, MD, PhD, J. Aoyagi, MD,
K. Iwamoto, MD, K. Ikeda, MD, PhD, Tokyo, Japan
Reply from the Authors: We thank Iwasaki et al. for sharing
their experience of MRI in CIDP and for raising the queries about
our study.1 We note that they also did not find central demyelinat-
ing lesions in their patients with CIDP but unlike our study they
also did not find cord atrophy. They raised three questions about
our findings.
Firstly, they inquired as to whether we looked for thoracic cord
atrophy. We used the method of Losseff et al.4, who had developed
a highly reproducible technique to measure atrophy of the spinal
cord related to anatomical, imaging, and measurement factors. We
specifically chose the C2/3 intervertebral disc as a caudal land-
mark since it is an uncommon site for disc protrusion5 and we did
not measure spinal cord area in the thoracic cord since the tech-
nique used at this level showed poor reproducibility.6
Secondly, they asked whether cervical spondylotic disease
could have contributed to the cord atrophy we demonstrated. We
only showed minor degenerative changes in four patients and did
not demonstrate any cord compression. We therefore do not feel
that the cervical degenerative disease contributed to the cord at-
rophy. We also specifically chose the C2/3 level to measure cord
atrophy as cord damage due to degenerative is relatively uncom-
mon at this site.
Thirdly, they wondered what factors contributed to the cord
atrophy in our series. We were not able to identify any specific
contributing factors which may in part reflect our small sample
size but we speculated that a dying back mechanism may be
important as has been suggested for diabetic neuropathy.7
We agree that further study of this finding is needed.
Mary M. Reilly, MD, Matilde Laura´, MD, London, UK
Copyright © 2005 by AAN Enterprises, Inc.
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Long-term outcome of endovascular stenting for
symptomatic basilar artery stenosis
To the Editor: We read with great interest the article by Yu et
al.1 demonstrating the effectiveness of stenting symptomatic basi-
lar artery (BA) stenosis for reducing the risk of recurrent stroke
and death. We would like to request clarification of specific issues
so that readers, particularly those skilled in neurointerventional
procedures, could be aided in decision-making.
The method section inaccurately described the type of wire
used to cross the lesion. It is unlikely that high-grade stenosis
would be crossed using 0.035-inch wire instead of the standard
0.014-inch microwire. The balloon types that are used for predila-
tation and the specific coronary stent types are known to affect
procedural outcome but were not mentioned. Under, over, or nom-
inal inflation of the stent-mounted balloon were not described. It
is unclear how long heparin was administered or the combination
of clopidogrel and aspirin following the procedure.
Prior to stenting, there was no description of the presenting
TIAs. Two patients were not treated with any type of medical
therapy but there are no details about the type of antiplatelet
treatment in the others. After the procedure, there is no mention
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of in-hospital length-of-stay after the procedures or worsening of
pre-existing deficits and TIAs. Some patients may require neuro-
critical care for several days with blood pressure and fluid aug-
mentation to maintain adequate cerebral perfusion.
In the legends of the selected images, there was no mention of
jailing perforating arteries; including loss of the left anterior inferior
cerebellar artery in case B. In the long-term outcome, five cases with
“dizzy spells” were not counted as possible vertigo or TIAs.
In the Discussion section, the authors conclude that the BA
stenting appeared to be safe and effective. This study has many
limitations to validate this conclusion. The cases where BA stent-
ing failed are not mentioned which makes it difficult to interpret
the success of current techniques.
We agree with the authors that further trials are needed to
better evaluate this controversial subject. However, prior to fur-
ther studies (involving the BA in particular), newer stents and
delivery systems designed for intracranial arteries are needed.
This is vital to avoid future setbacks in neurointerventional proce-
dures. Given the current available data and techniques, BA stent-
ing may be reserved for those patients with high-grade
symptomatic stenosis who did not respond to combined aspirin
and clopidogrel therapy.
Osama O. Zaidat, MD, MSc, Tony P. Smith, MD,
Michael J. Alexander, MD, Durham, NC
Reply from the Authors: We thank Zaidat et al. for their inter-
est in our work.1 The Discussion section mentioned the major
periprocedural complications that occurred in patients with acute
stroke and tandem stenosis.
Although different types of coronary stents and balloon angio-
plasty with a nominal pressure of 8 to 14 atm were used in this
case series, there was no correlation between types of balloon or
stents and periprocedural complications. Fifteen patients received
IV heparin for 24 hours followed by combination therapy with
clopidogrel and aspirin. Three patients were placed on oral antico-
agulants for 6 months and long-term clopidogrel therapy. Lesions
were crossed using 0.014-in microwire instead of 0.035-in micro-
wire as Zaidat noted. We appreciate the identification of this error
in our article.
Presenting TIAs, individual patient medications, length-of-stay
and neurointensive care management after the procedures were
not found to be associated with long-term outcome and therefore
not detailed in our article. Our figure was used to show the feasi-
bility of stenting for different types of stenotic lesions. The left
anterior inferior cerebellar artery (AICA) in case B was visible
distal to the vertebrobasilar junction in the post-stenting image.
Zaidat et al might have misidentified the loop between basilar
artery and left AICA in the prestenting image as AICA. The loop
was actually part of the left posterior inferior cerebellar artery.
Consistent with other report,2 our study also demonstrated that
symptomatic occlusion of pontine perforating arteries were very
uncommon. During follow-up, five patients reported transient
symptoms, including dizziness (2), sensation of head congestion
(1), neck pain (1), and hand incoordination (1).
It is well known that patients often experience nonspecific
symptoms after endovascular procedures that are not TIAs. We
identified no basilar artery stenting failure in our study, confirm-
ing other series reporting more than 95% success rate of stenting
for basilar artery stenosis and other intracranial atherosclerotic
lesions.2-4
Despite the limitations in retrospective study, our data showed
that with a mean 26.7 12.1-month follow-up, 83.3% of patients had
an excellent long-term outcome without vascular death. Therefore,
endovascular stenting for symptomatic basilar artery stenosis ap-
peared to be safe and effective in reducing stroke risk and death, and
should be further evaluated by randomized clinical trial.
W. Yu, MD, PhD, W.S. Smith, MD, PhD, V. Singh, MD,
N.U. Ko, MD, S.P. Cullen, MD, C.F. Dowd, MD, V.V. Halbach, MD,
R.T. Higashida, MD, San Francisco, CA
Copyright © 2005 by AAN Enterprises, Inc.
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NINDS AIREN neuroimaging criteria do
not distinguish stroke patients with and
without dementia
To the Editor: Ballard et al.1 report that in a group of stroke
patients, the neuroimaging component within the National Insti-
tute of Neurological Disorders and Stroke (NINDS) Internationale
pour la Recherche et l’Enseignement en Neurosciences (AIREN)
criteria2 for vascular dementia did not distinguish between pa-
tients with and without post-stroke dementia. In addition, groups
did not differ in number or size of infarcts. However, patients with
dementia had greater hippocampal atrophy. The authors conclude
that the NINDS AIREN neuroimaging criteria may need to be
revised, because they do not distinguish between stroke patients
with and without dementia. Although we agree with the authors
that the criteria may need revision, we would like to make some
critical comments concerning the research question of their study.
The NINDS AIREN criteria describe the clinical syndrome of
vascular dementia (VaD). Like in any other subtype of dementia,
clinical characteristics define whether or not a patient is de-
mented. The neuroimaging component of the criteria only serves
to determine the probability that the observed dementia is of
vascular origin. In the present sample of patients who all suffered
a cerebrovascular event, it was to be expected that the neuroimag-
ing criteria did not reveal any difference between dementia-groups
in terms of vascular burden. The authors merely show that a
patient may fulfill the radiologic criteria for VaD as defined by the
NINDS AIREN, and still not be demented. This is a reversal of
the diagnostic process, and reminds us that an MRI scan may
never be used in isolation to diagnose VaD. Furthermore, exclud-
ing patients who were demented prior to the stroke may have
introduced a selection bias, while this group has the highest prob-
ability of suffering VaD.
Moreover, the greater hippocampal atrophy of the demented
subgroup suggests that these patients may suffer from Alzheimer
disease (AD) rather than VaD, or have combined pathology. As the
authors propose, vascular pathology such as a stroke may interact
with preexisting subclinical Alzheimer pathology, resulting in
clinical dementia of the Alzheimer type. As the NINDS AIREN
criteria were not developed to detect AD, there is no reason to
expect that these criteria would be sensitive to detect patients
with AD.
Finally, it has been shown that the neuroimaging component of
the NINDS AIREN criteria has insufficient reliability,3 and this
might partly account for the inability to discriminate between
groups. Operational criteria have been put forward and tested,
resulting in a considerably improved reliability in experienced
readers.
W.M. van der Flier, PhD, E.C.W. van Straaten, MD,
F. Barkhof, MD, PhD, P. Scheltens, MD, PhD, Amsterdam, The
Netherlands
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